Physician profile
Stephen S Hwang
NPI 1598735813
$13,504.62
in general payments reported to CMS, 2019-2025
38 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $832 · 2021: $1,467 · 2022: $3,701 · 2023: $2,839 · 2024: $1,990 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,441.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,671.19 | 2019-2025 | Clareon, Acrysof Iq Panoptix Uv Iol, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $2,381.57 | 2022-2025 | Xiidra, Envista Aspire Toric Iol, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $1,805.56 | 2021-2024 | Tecnis Simplicity, Tecnis Iol, Tecnis Iol |
| Glaukos Corporation | $1,514.67 | 2019-2025 | Idosetr, Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Sun Pharmaceutical Industries INC. | $453.27 | 2019-2025 | Cequa, Xelpros, Bromsite |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $447.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $395.39 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $311.00 | 2020-2025 | Acthar |
| Rxsight INC | $288.38 | 2023-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $259.86 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $224.65 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $211.00 | 2024-2025 | Rayone Spheric, Rayone Aspheric, Rayone Emv |
| Dompe US, INC. | $201.61 | 2019-2025 | Oxervate |
| Harrow Eye, LLC | $181.78 | 2023-2025 | Iheezo, Vevye |
| Kala Pharmaceuticals, INC. | $161.02 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.93 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $151.06 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $147.85 | 2019 | |
| Nova Eye, INC. | $133.21 | 2024 | |
| Astellas Pharma US INC | $132.45 | 2023 | |
| Biotissue Holdings INC. | $128.90 | 2019-2023 | |
| Tearlab Corp | $118.77 | 2019-2023 | Tearlab Osmolarity System |
| Amgen INC. | $117.57 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $111.89 | 2021-2022 | |
| Ocular Therapeutix, INC. | $109.24 | 2020-2025 | Dextenza |
| Horizon Therapeutics Plc | $90.74 | 2019-2023 | Tepezza |
| Shire North American Group INC | $86.33 | 2019 | |
| Genentech USA, INC. | $81.04 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $73.65 | 2023 | Clarus |
| Tarsus Pharmaceuticals, INC. | $69.12 | 2024-2025 | Xdemvy |
| Heidelberg Engineering, INC. | $67.73 | 2023 | Spectralis |
| Lumibird Medical INC. | $63.60 | 2025 | |
| Thea Pharma INC. | $43.39 | 2023 | |
| Apellis Pharmaceuticals, INC. | $32.25 | 2025 | Syfovre |
| Beaver-Visitec International, INC. | $30.88 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.17 | 2021 | |
| Celularity INC. | $16.29 | 2021 | |
| Eyepoint US, INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.